Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Short Interest Down 32.1% in August

Key Points

• Short interest in Autolus Therapeutics decreased by 32.1% in August, totaling 10,110,000 shares, indicating a shift in investor sentiment.
• Analysts have mixed views on the stock, with five analysts rating it as a "Buy" and an average price target of $9.12, while Wells Fargo & Company has downgraded their price target from $6.00 to $5.00.
• Autolus reported earnings of ($0.18) per share, surpassing expectations and generating revenue of $13.50 million for the quarter.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totaling 10,110,000 shares, a drop of 32.1% from the August 15th total of 14,900,000 shares. Currently, 5.1% of the company's shares are short sold. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is currently 3.9 days. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is currently 3.9 days. Currently, 5.1% of the company's shares are short sold.

Analyst Upgrades and Downgrades

AUTL has been the topic of a number of analyst reports. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Wells Fargo & Company dropped their price target on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $9.12.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL opened at $1.32 on Tuesday. The stock has a market cap of $351.31 million, a price-to-earnings ratio of -1.57 and a beta of 1.87. The business has a 50 day simple moving average of $2.03 and a 200 day simple moving average of $1.83. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. On average, analysts predict that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Autolus Therapeutics in the 4th quarter worth approximately $26,000. Marex Group plc acquired a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $28,000. R Squared Ltd acquired a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $50,000. Invesco Ltd. lifted its holdings in Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. Finally, Delaney Dennis R acquired a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $55,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.